Oxyntomodulin: Deep Dive: How It Works, Who Uses It, and Safety Profile
Medically reviewed by Dr. James Whitfield, DO, FACOI
A comprehensive overview of Oxyntomodulin (OXM), a gut hormone with dual-agonist properties on GLP-1 and glucagon receptors, and its potential as a therapeutic agent for obesity and type 2 diabetes.
Oxyntomodulin: A New Frontier in Weight Management
Oxyntomodulin (OXM) is a naturally occurring peptide hormone that has garnered significant attention in the medical community for its potential role in combating obesity and related metabolic disorders. Released from the L-cells of the gut after a meal, OXM is a member of the proglucagon family, which also includes glucagon-like peptide-1 (GLP-1) and glucagon. Its unique dual-agonist action on both the GLP-1 and glucagon receptors sets it apart from other weight-loss medications, offering a multifaceted approach to appetite regulation and energy expenditure.
The Dual-Agonist Mechanism of Action
The therapeutic potential of Oxyntomodulin lies in its ability to simultaneously activate two key receptors involved in metabolic control: the GLP-1 receptor (GLP-1R) and the glucagon receptor (GCGR). This dual agonism results in a synergistic effect that promotes weight loss through several mechanisms:
Appetite Suppression: By activating the GLP-1R, OXM sends signals to the brain that reduce hunger and increase feelings of fullness (satiety). This leads to a natural reduction in calorie intake.
Increased Energy Expenditure: The activation of the GCGR by OXM stimulates the liver to increase energy expenditure, a process known as thermogenesis. This means the body burns more calories, even at rest.
Improved Glycemic Control: OXM has been shown to improve glucose tolerance and insulin sensitivity, making it a promising candidate for the treatment of type 2 diabetes.
This combined action of reducing energy intake while increasing energy expenditure makes Oxyntomodulin a powerful tool in the fight against obesity.
Who Can Benefit from Oxyntomodulin Therapy?
Oxyntomodulin therapy is being investigated for a range of conditions, primarily centered around metabolic health. The primary candidates for this treatment include:
Individuals with Obesity: Clinical trials have demonstrated that OXM can lead to significant weight loss in overweight and obese individuals.
Patients with Type 2 Diabetes: Due to its positive effects on glycemic control, OXM is being studied as a potential treatment for type 2 diabetes, both as a standalone therapy and in combination with other medications.
Patients with Non-Alcoholic Steatohepatitis (NASH): Emerging research suggests that OXM may have beneficial effects on liver fat and inflammation, making it a potential therapeutic option for NASH, a serious liver condition often associated with obesity.
Clinical Evidence and Research Highlights
Numerous studies have highlighted the efficacy and safety of Oxyntomodulin. A landmark study published in the journal Diabetes demonstrated that subcutaneous administration of OXM resulted in significant weight loss in obese and overweight subjects [1]. Another study in the International Journal of Obesity found that OXM increases energy expenditure in addition to decreasing energy intake [2]. More recent research has focused on developing long-acting analogs of OXM to improve patient convenience and adherence. For example, a study on the OXM analog LY3305677 showed improved glycemic control and weight loss in both healthy volunteers and subjects with type 2 diabetes [3].
| Feature | Oxyntomodulin (OXM) | Semaglutide (GLP-1 Agonist) | Tirzepatide (GLP-1/GIP Agonist) |
| :--- | :--- | :--- | :--- |
| Mechanism | Dual GLP-1/Glucagon Agonist | Selective GLP-1 Agonist | Dual GLP-1/GIP Agonist |
| Primary Effect | Reduces appetite, increases energy expenditure | Reduces appetite, slows gastric emptying | Reduces appetite, enhances insulin secretion |
| Administration | Injection (native form) | Injection | Injection |
| Weight Loss | Significant | Significant | Very Significant |
| Key Side Effects | Nausea, vomiting | Nausea, vomiting, diarrhea | Nausea, vomiting, diarrhea |
Safety Profile and Common Side Effects
Like other medications that act on the GLP-1 receptor, the most common side effects associated with Oxyntomodulin are gastrointestinal in nature. These include:
Nausea
Vomiting
Diarrhea
These side effects are typically mild to moderate in severity and tend to decrease over time as the body adjusts to the medication. The safety profile of OXM is considered to be similar to that of selective GLP-1 receptor agonists [3].
Key Takeaways
Oxyntomodulin is a dual-agonist peptide hormone that activates both GLP-1 and glucagon receptors.
It promotes weight loss by reducing appetite and increasing energy expenditure.
It has shown promise in the treatment of obesity, type 2 diabetes, and NASH.
The most common side effects are gastrointestinal and are generally manageable.
> Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider before starting any peptide therapy or making changes to your health regimen.
References
[1] Wynne, K., Park, A. J., Small, C. J., Patterson, M., Ellis, S. M., Murphy, K. G., ... & Bloom, S. R. (2005). Subcutaneous oxyntomodulin reduces body weight in overweight and obese subjects: a double-blind, randomized, controlled trial. Diabetes, 54(8), 2390-2395. https://diabetes.diabetesjournals.org/content/54/8/2390
[2] Wynne, K., Park, A. J., Small, C. J., Meeran, K., Ghatei, M. A., Frost, G. S., & Bloom, S. R. (2006). Oxyntomodulin increases energy expenditure in addition to decreasing energy intake in overweight and obese humans: a randomised controlled trial. International journal of obesity, 30(12), 1729-1736. https://www.nature.com/articles/0803344
[3] Coskun, T., Urva, S., O'Farrell, L., et al. (2022). 333-OR: Oxyntomodulin Analog LY3305677 (LY) Improves Glycemic Control and Weight Loss in Healthy Volunteers and Subjects with Type 2 Diabetes (T2D). Diabetes*, 71(Supplement_1), 333-OR. https://diabetes.diabetesjournals.org/content/71/Supplement_1/333-OR
---